

**UNITED STATES OF AMERICA  
BEFORE THE FEDERAL TRADE COMMISSION**





*ANI Pharmaceuticals, Inc., et al.*

FTC File No. 211-0101

Order to Maintain Assets, and no agreement, understanding, representation, or interpretation not contained in the Decision and Order, the Order to Maintain Assets, or the Consent Agreement may be used to vary or contradict the terms of udD(e)4 5To-0.02 Tc



*ANI Pharmaceuticals, Inc., et al.*

FTC File No. 211-0101

**ANI PHARMACEUTICALS INC.**

By: \_\_\_\_\_

Nikhil Lalwani  
President and Chief Executive Officer  
ANI Pharmaceuticals, Inc.

Date: \_\_\_\_\_

By: \_\_\_\_\_

Amanda P. Reeves, Esq.  
Patrick C. English, Esq.  
Latham & Watkins LLP  
Counsel for ANI Pharmaceuticals, Inc.

Date: \_\_\_\_\_









*ANI Pharmaceuticals, Inc., et al.*

FTC File No. 211-0101

**FEDERAL TRADE COMMISSION**

By: \_\_\_\_\_

Kari Wallace  
Attorney  
Bureau of Competition

\_\_\_\_\_  
James Weiss  
Deputy Assistant Director  
Bureau of Competition

\_\_\_\_\_  
Heather Johnson  
Deputy Director  
Bureau of Competition

\_\_\_\_\_  
Holly L. Vedova  
Director  
Bureau of Competition

Date: \_\_\_\_\_